{
  "symbol": "REGN",
  "year": 2023,
  "period": "Q2",
  "competition_summary": [
    {
      "competitor": "Company",
      "mentions": 4,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Libtayo",
      "mentions": 3,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Dupixent",
      "mentions": 4,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "the Antibody Collaboration",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "LCA",
      "mentions": 2,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Regeneron",
      "mentions": 10,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "the IO Collaboration",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Bayer Collaboration Revenue",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Total Bayer",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Bayer",
      "mentions": 5,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Roche Collaboration Revenue Three Months Ended June 30",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Roche",
      "mentions": 2,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Change Research",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Change Direct",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Linvoseltamab",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Reimbursement of research and",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "the Sanofi Antibody Collaboration",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "FDA",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    }
  ]
}